Argentina pays close attention to Soberana 02 vaccine's advances
Buenos Aires, Feb 23 (Prensa Latina) The advances of the Cuban Soberana 02 vaccine candidate, the first Latin American vaccine against Covid-19, were highlighted on Tuesday by the Director of Science and Innovation of the company BioCubaFarma, Rolando Perez Rodriguez.
In an exclusive interview with the Pagina 12 newspaper, the Doctor in Biological Sciences noted that as of the second semester of 2021, Cuba will be able to immunize its population and provide doses to the countries that require them.
Leading up to the 3rd phase of Soberana 02 clinical trial, with a production of 100 million doses for 2021, Perez Rodriguez underscored that at the end of March, another Cuban vaccine candidate, Abdala, developed by the Center for Genetic Engineering and Biotechnology (CIGB), will join the last phase of clinical trials.
'It's all about sharing with the world what we are, the response Cuba can provide to the pandemic problem,' the doctor pointed out, after explaining that his nation has the production capacity to offer it to other countries that demand it.
On answering to a question about the reasons for Cuba to develop its own vaccine, Perez Rodriguez set out that one of the strengths of his country's biotechnology industry is precisely the development of vaccines.
'From the time the world began to make potential deals, at very high prices, to acquire vaccines that did not yet exist, we realized that vaccines were not going to be enough. For us, the tightening of the US economic blockade, especially during Donald Trump's term, complicates our access to certain products,' he emphasized.
The expert also added that despite such difficulty, they are moving forward. The idea of the vaccine is to be able to show that just as Cuba needs the rest of the world, this Caribbean country can also contribute a lot to it, he concluded.
|By the minute||Most read|